- Baird has upgraded Cardinal Health ( NYSE: CAH ) to outperform from neutral after the drug wholesaler raised its 2023 profit guidance and its quarterly results beat on the top and bottom lines .
- Analyst Eric Coldwell said that the company "deserves to be on board for our positive drug distributor sector call."
- He noted that the pharma segment is "narrowing long-running profit growth gap with peers."
- Coldwell added that Cardinal Health ( CAH ) can be obtained at P/E and EBITDA discounts compared to peers.
- Read why Seeking Alpha contributor Low Budget Dividend Investing, who considers Cardinal Health ( CAH ) a hold, says that it is "a recession-resistant stock."
For further details see:
Cardinal Health upgraded to outperform at Baird as 'value trap label' ready to end